公开(公告)号：US20190192543A1

公开(公告)日：2019-06-27

申请号：US16328493

申请日：2017-08-25

申请人： IDOGEN AB

发明人： Peter ERICSSON ,  Hans Olov SJÖGREN

IPC分类号： A61K31/708 ,  A61P37/08 ,  A61P37/06 ,  A61K31/166 ,  A61K31/7068 ,  A61K31/165 ,  A61K31/436 ,  A61K9/00

CPC分类号： A61K31/708 ,  A61K9/0019 ,  A61K31/165 ,  A61K31/166 ,  A61K31/436 ,  A61K31/7068 ,  A61P37/06 ,  A61P37/08 ,  C07C1/00 ,  C12N9/0069

摘要： The present invention relates to ex vivo methods using guadecitabine, the compound of formula (I) and related uses.

公开(公告)号：US10328133B2

公开(公告)日：2019-06-25

申请号：US12867426

申请日：2009-02-13

申请人： David J. Mooney ,  Omar Ali ,  Glenn Dranoff

发明人： David J. Mooney ,  Omar Ali ,  Glenn Dranoff

IPC分类号： A61K45/06 ,  A61K38/19 ,  A61K39/39 ,  A61K39/00 ,  A61K31/7088 ,  A61K39/385 ,  A61K31/4745 ,  A61K31/708

摘要： The present invention comprises compositions, methods and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.

公开(公告)号：US10308938B2

公开(公告)日：2019-06-04

申请号：US15319132

申请日：2015-06-18

申请人： YALE UNIVERSITY

发明人： Margarita Dominguez-Villar ,  David A. Hafler

IPC分类号： A61K39/21 ,  C12N15/113 ,  A61K31/4745 ,  C07K16/28 ,  A61K31/437 ,  A61K31/708 ,  A61K31/7088 ,  A61K39/395 ,  G01N33/569 ,  A61K39/00

摘要： The present invention includes compositions and methods of inhibiting or activating TLR7 signaling. In one aspect, a composition includes an inhibitor of TLR7 signaling is described, where the inhibitor of TLR7 signaling is a TLR7 inhibitory oligonucleotide, a TLR7 antibody, or a TLR7 antagonist. In another aspect, a composition and method are described for preventing and treating viral infection of a T cell in a subject. Methods for decreasing T cell proliferation by administering a composition with a TLR7 ligand or agonist or inducing T cell anergy in a subject by stimulating T cells with a TLR7 ligand or agonist are also described.

公开(公告)号：US10292996B2

公开(公告)日：2019-05-21

申请号：US15082207

申请日：2016-03-28

申请人： The Trustees of Columbia University in the City of New York

发明人： Michio Hirano ,  Caterina Garone

IPC分类号： A61K31/708 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076

摘要： The present invention provides a pharmacological therapy using deoxyribonucleoside monophosphate compounds, or mixtures thereof, for the treatment of human genetic diseases. The compounds of the present invention can be used to treat mitochondrial DNA depletion syndromes or other disorders of unbalanced nucleotide pools, such as thymidine kinase 2 (TK2) deficiency.

公开(公告)号：US10258677B2

公开(公告)日：2019-04-16

申请号：US15135255

申请日：2016-04-21

申请人： President and Fellows of Harvard College ,  Dana-Farber Cancer Institute, Inc.

发明人： David J. Mooney ,  Omar Abdel-Rahman Ali ,  Glenn Dranoff

IPC分类号： A61K38/19 ,  A61K39/00 ,  A61K39/39 ,  A61K31/708 ,  A61K31/7088 ,  A61K31/4745 ,  A61K45/06

摘要： The present invention comprises compositions, methods, and devices for creating an infection-mimicking environment within a polymer scaffold to stimulate antigen-specific dendritic cell activation. Devices of the present invention are used to provide protective immunity to subjects against infection and cancer.

公开(公告)号：US20190100552A1

公开(公告)日：2019-04-04

申请号：US16134520

申请日：2018-09-18

申请人： Epizyme, Inc.

发明人： Edward J. OLHAVA ,  Richard CHESWORTH ,  Roy M. POLLOCK ,  Lei JIN

IPC分类号： C07H19/16 ,  C07H19/14 ,  C07D473/34 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/7068 ,  A61K31/708 ,  A61K31/7064

摘要： The present invention relates to DOT1L inhibitors and methods of identifying, designing, or optimizing them. The present invention also relates to crystals of DOT1L-inhibitor complexes, the crystal structures thereof, and the use of the crystal structures. Also disclosed are pharmaceutical compositions containing these DOT1L inhibitors and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

公开(公告)号：US20190022122A1

公开(公告)日：2019-01-24

申请号：US16060895

申请日：2016-12-09

申请人： Centre National de la Recherche Scientifique (C.N.R.S)

发明人： José-Manuel CANCELA ,  Sabine DE LA PORTE ,  Antoine DE ZELICOURT

IPC分类号： A61K31/7084 ,  A61K31/708 ,  A61K31/496 ,  A61P21/00

摘要： The present invention relates to the field of medicine. It relates more particularly to the use of compounds for preventing and/or treating, in a subject, myopathy, typically muscular dystrophy or cardiomyopathy, or muscular trauma. The invention also relates to the compositions, in particular pharmaceutical compositions comprising such compounds, as well as their uses for preventing and/or treating muscular myopathy or trauma. The compounds and compositions according to the invention may typically be advantageously used to prevent and/or treat muscular dystrophy, cardiomyopathy or muscular trauma, preferably Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and/or a characteristic symptom or anomaly of DMD or BMD.

公开(公告)号：US10087209B2

公开(公告)日：2018-10-02

申请号：US15568692

申请日：2016-04-27

申请人： KU LEUVEN RESEARCH & DEVELOPMENT

发明人： Piet Herdewijn ,  Steven De Jonghe ,  Shrivinas Dumbre ,  Chao Liu

IPC分类号： C07H19/10 ,  C07H19/20 ,  A61K31/7076 ,  A61K45/06 ,  A61P35/00 ,  A61K31/708 ,  A61K31/7072 ,  A61K31/7068 ,  A61P31/20

摘要： The present invention relates to novel pro-drugs of L-2′-deoxythreose nucleoside phosphonates, such as phosphoramidate, phosphorodiamidate and phospho-diester pro-drugs. The invention also relates to a process for preparing these novel prodrugs of nucleoside phosphonates. The invention also relates to the use of these novel phosphonate-modified nucleosides to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with viruses belonging to the HBV family.

公开(公告)号：US20180243326A1

公开(公告)日：2018-08-30

申请号：US15754842

申请日：2016-08-24

申请人： StaGen Co., Ltd.

发明人： Takeshi NISHINO ,  Naoyuki KAMATANI

IPC分类号： A61K31/708 ,  A61K31/426

摘要： A problem to be solved by the present invention is to provide a substance having an effect of increasing intracellular ATP and, particularly, a potent ATP enhancer far surpassing the increasing effect of inosine or febuxostat alone.A human or animal intracellular ATP enhancer comprising a combination of A) and B): A) a xanthine oxidase/xanthine dehydrogenase inhibitor or a pharmaceutically acceptable salt thereof; and B) any one or more compounds selected from inosine, inosinic acid, hypoxanthine, and pharmaceutically acceptable salts thereof.

公开(公告)号：US10052342B2

公开(公告)日：2018-08-21

申请号：US15427964

申请日：2017-02-08

申请人： ALIOS BIOPHARMA, INC.

发明人： Lawrence M. Blatt ,  Leonid Beigelman ,  Natalia Dyatkina ,  Julian Alexander Symons ,  David Bernard Smith

IPC分类号： A01N43/04 ,  A61K31/70 ,  A61K31/7068 ,  A61K31/708 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/7052 ,  A61K31/706 ,  A61K31/7064

CPC分类号： A61K31/7068 ,  A61K31/7052 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708

摘要： Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.